Evidence map›Paper›PMID 41103507›Full record

ReviewFrontiers in aging2025

Natural autoantibodies and their functional therapeutic roles in intravenous immunoglobulin.

Maria Giovanna Danieli, Ilaria Claudi, Elena Buti, Luca Gammeri, Sebastiano Gangemi, Yehuda Julyus Shoenfeld

Abstract readReview
In one paragraph

Review in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maria Giovanna DanieliPostgraduate School in Allergy and Clinical Immunology, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.
Ilaria ClaudiPostgraduate School in Allergy and Clinical Immunology, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.
Elena ButiPostgraduate School in Allergy and Clinical Immunology, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.
Luca GammeriSchool of Allergy and Clinical Immunology, University of Messina, Messina, Italy.
Sebastiano GangemiSchool of Allergy and Clinical Immunology, University of Messina, Messina, Italy.
Yehuda Julyus ShoenfeldReichman University, Herzelia, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural autoantibodies (NAbs) are a key component of the immune system, produced mainly by B-1 cells without prior antigenic stimulation. These antibodies exhibit broad reactivity toward both self and non-self antigens and contribute to immune homeostasis by clearing apoptotic cells and cellular debris, modulating immune responses, preventing autoimmune reactions, and promoting tissue repair. NAbs are present in intravenous immunoglobulin (IVIg) preparations, where they play an important role in the therapeutic effects observed in autoimmune, inflammatory, and neurodegenerative diseases. Importantly, NAbs of the IgG class contained in commercial IVIg originate from large-scale pooling of sera from thousands of healthy donors, and are recovered after multiple enrichment and purification steps during the manufacturing process. This review provides a comprehensive overview of the physiological functions of NAbs and their involvement in the mechanisms of action of IVIg. The review particularly focuses on anti-idiotypic antibodies within IVIg, which can neutralize pathogenic autoantibodies in diseases such as systemic lupus erythematosus, antiphospholipid syndrome, and pemphigus vulgaris. In the neurological field, NAbs in IVIg have been shown to target misfolded proteins such as amyloid-beta and alpha-synuclein, reduce neuroinflammation, and support neuronal survival, with promising results in Alzheimer's disease, Parkinson's disease, autoimmune encephalitis, and small fiber neuropathy. Similarly, in dermatological and systemic autoimmune diseases, NAbs contribute to immune regulation and the neutralization of tissue-damaging autoantibodies. Enhancing the therapeutic potential of IVIg through selective enrichment of beneficial NAb subsets could represent a promising direction for future research aimed at improving outcomes in a wide range of immune-mediated diseases.

Indexed as

Alzheimer’s diseasesautoimmunityconnective tissue diseasesepigeneticintravenous immunoglobulinnatural autoantibodiesParkinson’s diseasesmall fiber neuropathy

Identifiers

PMID41103507
PMCPMC12522042

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.